Trump Administration Officials Block FDA Effort to Expedite Psilocybin Review for Severe Depression Treatment

Officials from the Trump administration intervened to block an effort by the U.S. Food and Drug Administration (FDA) to expedite the review process for a psychedelic treatment aimed at addressing severe depression, according to information obtained. The FDA had proposed granting “breakthrough therapy” designation to psilocybin, a compound found in certain psychedelic mushrooms, which would have allowed for faster development and regulatory review of the treatment.

The decision reportedly halted progress on what some researchers consider a promising avenue for treating mental health conditions. The FDA’s proposal sought to prioritize psilocybin due to its potential benefits for individuals with severe depression who may not respond to traditional treatments. However, officials within the administration opposed this move, effectively preventing the agency from advancing its plans. Further details regarding the rationale behind this decision or subsequent actions remain unclear at this time.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: February 4, 2026

Author

GOAI